336 related articles for article (PubMed ID: 31951278)
1. A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE.
van Dam LS; Osmani Z; Kamerling SWA; Kraaij T; Bakker JA; Scherer HU; Rabelink TJ; Voll RE; Alexander T; Isenberg DA; van Kooten C; Teng YKO
Rheumatology (Oxford); 2020 Oct; 59(10):2734-2745. PubMed ID: 31951278
[TBL] [Abstract][Full Text] [Related]
2. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
Kraaij T; Kamerling SWA; de Rooij ENM; van Daele PLA; Bredewold OW; Bakker JA; Bajema IM; Scherer HU; Toes REM; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
[TBL] [Abstract][Full Text] [Related]
3. Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results.
Kraaij T; Arends EJ; van Dam LS; Kamerling SWA; van Daele PLA; Bredewold OW; Ray A; Bakker JA; Scherer HU; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
Nephrol Dial Transplant; 2021 Jul; 36(8):1474-1483. PubMed ID: 32591783
[TBL] [Abstract][Full Text] [Related]
4. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
Stohl W; Hiepe F; Latinis KM; Thomas M; Scheinberg MA; Clarke A; Aranow C; Wellborne FR; Abud-Mendoza C; Hough DR; Pineda L; Migone TS; Zhong ZJ; Freimuth WW; Chatham WW; ;
Arthritis Rheum; 2012 Jul; 64(7):2328-37. PubMed ID: 22275291
[TBL] [Abstract][Full Text] [Related]
5. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus.
Sohrabian A; Parodis I; Carlströmer-Berthén N; Frodlund M; Jönsen A; Zickert A; Sjöwall C; Bengtsson AA; Gunnarsson I; Rönnelid J
Arthritis Res Ther; 2019 Nov; 21(1):259. PubMed ID: 31783909
[TBL] [Abstract][Full Text] [Related]
6. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
7. Baseline autoantibody profiles predict normalization of complement and anti-dsDNA autoantibody levels following rituximab treatment in systemic lupus erythematosus.
Tew GW; Rabbee N; Wolslegel K; Hsieh HJ; Monroe JG; Behrens TW; Brunetta PG; Keir ME
Lupus; 2010 Feb; 19(2):146-57. PubMed ID: 19946034
[TBL] [Abstract][Full Text] [Related]
8. Differential clearance mechanisms, neutrophil extracellular trap degradation and phagocytosis, are operative in systemic lupus erythematosus patients with distinct autoantibody specificities.
Chauhan SK; Rai R; Singh VV; Rai M; Rai G
Immunol Lett; 2015 Dec; 168(2):254-9. PubMed ID: 26434792
[TBL] [Abstract][Full Text] [Related]
9. Are lupus animal models useful for understanding and developing new therapies for human SLE?
Moore E; Putterman C
J Autoimmun; 2020 Aug; 112():102490. PubMed ID: 32535128
[TBL] [Abstract][Full Text] [Related]
10. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus.
Hui-Yuen JS; Nguyen SC; Askanase AD
Lupus; 2016 Sep; 25(10):1086-96. PubMed ID: 27497253
[TBL] [Abstract][Full Text] [Related]
11. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
12. Belimumab for systemic lupus erythematosus: a practice-based view.
Parodis I; Axelsson M; Gunnarsson I
Lupus; 2013 Apr; 22(4):372-80. PubMed ID: 23553780
[TBL] [Abstract][Full Text] [Related]
13. Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies.
Petricca L; Gigante MR; Paglionico A; Costanzi S; Vischini G; Di Mario C; Varriano V; Tanti G; Tolusso B; Alivernini S; Grandaliano G; Ferraccioli G; Gremese E
Front Med (Lausanne); 2020; 7():553075. PubMed ID: 33195302
[TBL] [Abstract][Full Text] [Related]
14. B cell alterations during BAFF inhibition with belimumab in SLE.
Ramsköld D; Parodis I; Lakshmikanth T; Sippl N; Khademi M; Chen Y; Zickert A; Mikeš J; Achour A; Amara K; Piehl F; Brodin P; Gunnarsson I; Malmström V
EBioMedicine; 2019 Feb; 40():517-527. PubMed ID: 30593436
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases.
Sjöwall C; Hjorth M; Eriksson P
Lupus; 2017 Oct; 26(12):1333-1338. PubMed ID: 28162031
[TBL] [Abstract][Full Text] [Related]
16. Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.
Reddy V; Klein C; Isenberg DA; Glennie MJ; Cambridge G; Cragg MS; Leandro MJ
Rheumatology (Oxford); 2017 Jul; 56(7):1227-1237. PubMed ID: 28407142
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial.
Shipa M; Embleton-Thirsk A; Parvaz M; Santos LR; Muller P; Chowdhury K; Isenberg DA; Doré CJ; Gordon C; Ehrenstein MR;
Ann Intern Med; 2021 Dec; 174(12):1647-1657. PubMed ID: 34698499
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab.
Simonetta F; Allali D; Roux-Lombard P; Chizzolini C
Joint Bone Spine; 2017 Mar; 84(2):235-236. PubMed ID: 27238199
[No Abstract] [Full Text] [Related]
19. Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus.
Nakayamada S; Iwata S; Tanaka Y
Int J Rheum Dis; 2015 Feb; 18(2):208-18. PubMed ID: 25557245
[TBL] [Abstract][Full Text] [Related]
20. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
